We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Northw.Bio Regs | LSE:NWBS | London | Ordinary Share | COM SHS USD0.001 (REGS) |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 13.00 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
RNS Number : 1203B Northwest Biotherapeutics Inc 12 August 2008 For Immediate Release 12 August 2008 Northwest Biotherapeutics ("NWBT" or the "Company") Management and Board Change Northwest Biotherapeutics, Inc. (AIM: NWBS and NWBT; OTC BB: NWBO.US), announced that on August 12, 2008, Anthony P. Deasey resigned as Senior Vice President of Finance, Chief Financial Officer and ex officio Director of Northwest Biotherapeutics, Inc. (the "Company") in order to pursue a personal entrepreneurial opportunity. Day to day responsibilities related to the Company's accounting and financial administration will remain with the Company controller. Other financial functions, including pursuit of funding opportunities, will be carried out by the Company's Chief Executive Officer, Dr. Alton Boynton, and the Company's Chairperson, Ms. Linda Powers. Although Mr. Deasey will discontinue his roles as an officer and ex officio director of the Company effective August 12, Mr. Deasey's employment with the Company will continue until September 30, 2008, to help facilitate the transition. In addition, from October 1, 2008, through November 15, 2008, Mr. Deasey will provide part-time consulting services to the Company, and will receive consulting fees at a rate equal to 50% of his current monthly salary. Dr. Alton Boynton, President and Chief Executive Officer commented: "We would like to thank Tony for his work at Northwest Biotherapeutics over the last year. We wish him well in his future entrepreneurial endeavours and are pleased to have him continue his services as a part-time consultant to the Company while he transitions to his new opportunity." Mr. Deasey added, "I enjoyed working with the Northwest Biotherapeutics team, over the past year, to advance this exciting technology, and wish them continued success." For further information, please contact: Northwest Biotherapeutics Alton Boynton, President and Chief Executive Officer +1 240-497-9024 Buchanan Communications Lisa Baderoon (lisab@buchanan.uk.com) / Mary-Jane +44 (0)20 7466 5000 Johnson / Catherine Breen Collins Stewart Adam Cowen/Tim Mickley +44 (0)20 7523 8230 This information is provided by RNS The company news service from the London Stock Exchange END BOAUUAVRWVRWARR
1 Year Northw.Bio Regs Chart |
1 Month Northw.Bio Regs Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions